An announcement from Quest Diagnostics ( (DGX) ) is now available.
On March 19, 2025, Quest Diagnostics hosted an Investor Day to discuss strategies for sustainable growth and long-term shareholder value. The company highlighted its focus on advanced diagnostics, aiming for double-digit revenue growth in key clinical areas. Quest is leveraging macro trends like demographic shifts and innovations in lab diagnostics to enhance its market position. The company anticipates a 4% to 5% revenue CAGR and a 7% to 9% adjusted EPS CAGR beyond 2025, driven by investments in technology and expanded health plan network access.
More about Quest Diagnostics
Quest Diagnostics is a leading provider of diagnostic information services, serving approximately 50% of US hospitals and physicians annually and reaching one-third of US adults. The company operates around 8,000 patient access sites and employs over 55,000 people. Quest Diagnostics is well-positioned in the nearly $90 billion US lab market and is expanding its presence in the Canadian lab market through LifeLabs.
YTD Price Performance: 14.87%
Average Trading Volume: 1,053,218
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $19.14B
For detailed information about DGX stock, go to TipRanks’ Stock Analysis page.